DC-34
DC-34 is a selective stabilizer of MYC G-quadruplexes (G4s), with measured Kd values of 9.4 μM (FIA), 1.4 μM (SPR), and 16.5 μM (NMR) across different assays. DC-34 downregulates MYC levels in cancer cells in a G4-dependent manner, reduces cell viability, and induces G0-G1 cell cycle arrest and p16-marked senescence in MYC-driven multiple myeloma cells. DC-34 can serve as a probe for G4-dependent gene regulation studies and is applicable to research on multiple myeloma.
For research use only. We do not sell to patients.
- CAS No.: 1966107-70-9
- Formula: C24H25F3N2O3
- Molecular Weight:446.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| AMO1 | IC50 |
5.92 μM
Compound: 28
|
Cytotoxicity against human AMO1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human AMO1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33355454] |
| CA46 | IC50 |
9.2 μM
Compound: 28
|
Cytotoxicity against human CA46 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human CA46 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33355454] |
| Fibroblast | IC50 |
19.55 μM
Compound: 28
|
Cytotoxicity against human Fibroblast cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human Fibroblast cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33355454] |
| HEK-293T | IC50 |
34 μM
Compound: 28
|
Cytotoxicity against human HEK293T cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HEK293T cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33355454] |
| KMM-1 | IC50 |
4.13 μM
Compound: 28
|
Cytotoxicity against human KMM-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human KMM-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33355454] |
| KMS-12-PE | IC50 |
5.3 μM
Compound: 28
|
Cytotoxicity against human KMS-12-PE cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human KMS-12-PE cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33355454] |
| L-363 | IC50 |
3.4 μM
Compound: 28
|
Cytotoxicity against human L-363 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human L-363 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33355454] |
| NCI-H929 | IC50 |
4.89 μM
Compound: 28
|
Cytotoxicity against human NCI-H929 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human NCI-H929 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33355454] |
In Vitro
DC-34 (up to 100 μM; 24-72 h) inhibits L363 multiple myeloma cell viability with IC50 values of 3.4 μM (24 h), 3.4 μM (48 h), and 3.1 μM (72 h)[1].
DC-34 (0.1-10 μM; 4-72 h) potently and selectively reduces MYC protein levels in L363 multiple myeloma cells (IC50 = 1.9 μM at 24 h) by a MYC G-quadruplex-dependent mechanism, with no effect in cells lacking the MYC G-quadruplex promoter sequence[1].
DC34 (2.5-7.5 μM; 24-48 h) potently downregulates MYC transcription in L363 multiple myeloma cells in vitro in a time- and dose-dependent manner, with minimal effects on other tested G4-driven oncogenes[1].
DC34 (5 μM; up to 75 min) does not affect MYC protein stability in L363 multiple myeloma cells, indicating its inhibitory effect on MYC occurs at the transcriptional level[1].
DC50-34 (5 μM; 48 h) induces G0/G1 cell cycle arrest (63.54% of cells) and senescence marker p16 expression in L363 multiple myeloma cells after 48 h of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:L363 multiple myeloma cells, CA46 Burkitt's lymphoma cells, 293T cells transfected with CMV-MYC plasmid
-
Concentration:0.1, 1 and 10 μM
-
Incubation Time:4, 24, 48 and 72 h
-
Result:At 10 μM, reduced MYC protein levels in L363 cells to 0.4% of untreated levels.
Had an IC50 of 1.9 μM for MYC protein inhibition in L363 cells at 24 h.
Sustained reduced MYC protein levels in L363 cells over 72 h when treated with 5 μM.
Up to 5 μM had no effect on MYC protein levels in CA46 cells (lacking the MYC G-quadruplex promoter) and 293T cells transfected with CMV-MYC (lacking the MYC G-quadruplex).
-
Cell Line:L363 multiple myeloma cells
-
Concentration:2.5-7.5 μM
-
Incubation Time:24 h, 48 h
-
Result:Reduced MYC mRNA levels in a time- and dose-dependent manner, with dramatic decreases observed at 5 μM (24 h and 48 h) and 7.5 μM (48 h).
Had significantly weaker effects on the mRNA levels of other G4-driven genes (BCL2, HIF1α, KRAS, VEGFA).
-
Cell Line:L363 multiple myeloma cells
-
Concentration:5 μM
-
Incubation Time:48 h
-
Result:Caused 63.54% of L363 cells to accumulate in the G0/G1 phase, compared to 49.37% of untreated cells.
Induced p16 expression, a marker of senescence, especially at high concentrations.
-
Cell Line:L363 multiple myeloma cells
-
Concentration:5 μM (co-treated with 10 μg/mL Cycloheximide (HY-12320))
-
Incubation Time:up to 75 min
-
Result:Did not alter the stability of MYC protein over 75 min, as MYC degradation rates were identical in treated and untreated cells.
Chemical Information
-
CAS No. 1966107-70-9
-
Molecular Weight 446.47
-
Formula C24H25F3N2O3
-
SMILES
O=C(NC1=CC=C(C=C1)C(F)(F)F)C2=C(OC3=CC=C(O)C(=C32)CN4CCCCCC4)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
CRISPRi/CRISPRa gene-regulation editing
CRISPRi and CRISPRa use catalytically inactive Cas9, typically SpCas9 D10A/H840A, as an RNA-guided DNA-binding platform that targets genomic loci through sgRNA complementarity and an adjacent PAM without generating Cas9 nuclease-mediated DNA cleavage. CRISPRi represses transcription by recruiting dCas9 alone or dCas9 fused to repressor domains such as KRAB to promoters or transcription start site regions, while CRISPRa activates transcription by recruiting activation domains such as VP64, VPR, or SAM components to promoter-proximal regions. The primary readout is target-gene expression change, commonly measured by RT-qPCR, RNA-seq, reporter fluorescence, or protein-level assays, and the readout reflects transcriptional repression or activation at the targeted endogenous locus.
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)